New mRNA Vaccine Reduces Risk of Melanoma Recurrence by Over 40 Percent
The vaccine is personalized to a patient’s tumor, and results from the Phase 3 trial are yet another example of the promise of mRNA vaccines in treating cancer.
This story was automatically imported from our syndicated feed coverage. Full updates are being tracked closely as more details emerge from local correspondents and global news wires.
Our editorial team is continuously monitoring this topic to bring you the latest developments. Check back regularly for detailed follow-up articles, background analyses, and video broadcasts from the scene.
Reporting sponsored by News Portal Syndicated Coverage.